Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy. The ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to ...

The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer. Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we ...

TUCSON, Ariz., Sept. 28, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the expanded use of the VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) and metastatic ...

Mortality within 30 days of receiving checkpoint inhibitor immunotherapy: An Australian multicenter review. % of LA pts I ordered the test 74 31.2 50, 100 % of LA pts another ONC ordered the test 11 ...

Dublin, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...